Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ritobegron in Healthy Volunteers
NCT02259907Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2003
- Primary completion
- Feb 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of ritobegron in overactive bladder (OAB) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with clinically significant findings in physical examination, Number of subjects with clinically significant changes in vital signs and 4 more. Started May 2003; status: completed.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02259907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259907.